Schulte Roth & Zabel represented Commodore Capital in the transaction. In connection with its acquisition of AlmataBio, Avalo Therapeutics, Inc. issued a PIPE consisting of preferred...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here